Elite in Myoglobinuria Recurrent

John Vissing

Centre De Référence De Pathologie Neuromusculaire Paris Est, 
EE 
Elite in Myoglobinuria Recurrent
Centre De Référence De Pathologie Neuromusculaire Paris Est, 
EE 
OverviewLocationsClinical Research

Overview

John Vissing practices in Estonia. Mr. Vissing is rated as an Elite expert by MediFind in the treatment of Myoglobinuria Recurrent. His top areas of expertise are Limb-Girdle Muscular Dystrophy, Myasthenia Gravis, Limb-Girdle Muscular Dystrophy Type 2I, and Myoglobinuria Recurrent.

His clinical research consists of co-authoring 372 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 11 articles in the study of Myoglobinuria Recurrent.

Gender
Male

Locations

Centre De Référence De Pathologie Neuromusculaire Paris Est, Estonia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy
A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy
Enrollment Status: Completed
Publish Date: May 08, 2024
Intervention Type: Drug
Study Drug: REN001
Study Phase: Phase 2
A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A)
A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A)
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2024
Intervention Type: Drug
Study Drug: (RS)-Baclofen, Naltrexone Hydrochloride and D-Sorbitol
Study Phase: Phase 3
A Multicenter Open-Label Study on the Safety and Efficacy of Deflazacort (Emflaza) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
A Multicenter Open-Label Study on the Safety and Efficacy of Deflazacort (Emflaza) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
Enrollment Status: Terminated
Publish Date: June 27, 2022
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

372 Total Publications

Novel treatments for myasthenia gravis.
Novel treatments for myasthenia gravis.
Journal: International review of neurobiology
Published: October 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Vissing's expertise for a condition
ConditionClose
View All 20 Distinguished Conditions
View All 27 Advanced Conditions
View All 54 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile